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Introduction
Hepatocellular carcinoma (HCC) is one of  the most 
lethal and prevalent liver [1, 2]. HCC is highly prevalent 
in many Asian countries, accounting for 80% of  victims 
worldwide [3, 4]. Most HCC patients show chronic
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hepatitis or cirrhosis caused by persistent infection with 
hepatitis B virus (HBV) or hepatitis C virus (HCV) 
[5-7]. Aflatoxin B1 (AFB1) is also very important in the 
onset of  HCC. Hepatectomy is regarded as the optimal 
curative treatment for HCC at present; however, the 
postoperative outcome remains unsatisfactory [8]. 
Its underlying biological mechanism remains unclear 
and no well-documented drug and targeting has been 
approved to date [9]. 
Cyclooxygenase 2 (Cox-2) is expressed highly 
in cancer and it is found to be implicated in tumor 
progression, and its inhibition can reduce tumor growth 
and augment therapy [10, 11]. Glutathione S-transferase 
Pi (GST-Pi) is a subgroup of  GST family, which provides 
cellular protection against free radical and carcinogenic 
compounds due to its detoxifying function [12]. There 
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Abstract 
Background: Hepatocellular carcinoma (HCC) is one of  the most common and aggressive cancers worldwide, and the 
pathogenesis is complicated at present. There iare few effective therapeutic measures, and novel therapeutic strategies are 
urgently required to improve clinical outcome. Ginkgo biloba extract (EGb) is reported to have an anti-cancer activity. 
Objectives: To explore the effect of  EGb on expressions of  cyclooxygenase-2 (Cox-2) and glutathione S-transferase Pi 
(GST-Pi) in the pathogenesis of  HCC. 
Methods: 120 Wistar rats were divided into three groups at random: normal control group (control group), HCC risk group 
without treatment (HCC risk group), HCC risk group treated with EGb (EGb group); n=40, respectively. The HCC risk in 
rat was induced by aflatoxin B1 injection. At the end of  13-week, 33-week, 53-week and 73-week, 10 rats in each group were 
killed and the relevant samples were collected. 
Results: The mRNA and protein expressions of  Cox-2 and GST-Pi were measured by real-time reverse transcription 
polymerase chain reaction, immunohistochemical analysis and western-blot. When compared with those in the control 
group in 73-week, the mRNA and protein expressions of  GST-Pi in EGb group were weaker than those in HCC risk group 
in 73-week. However, the mRNA and protein expressions of  Cox-2 in HCC risk group were increased than that of  control 
group, and there was no statistical difference for mRNA and protein expressions of  Cox-2 between HCC risk group and 
EGb group.
Conclusion: EGb can regulate the expression of  GST-Pi, but it does not seem to have an effect on Cox-2 expression in the 
liver of  HCC risk rats.
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was no report studying the expressions of  Cox-2 and 
GST-Pi in the HCC rats induced by AFB1. In this study, 
we investigated the association of  Cox-2 and GST-Pi 
expressions with HCC risk in rats induced by AFB1.
  Ginkgo Biloba is one of  the oldest living tree species 
and it has been described as a living fossil. Its beneficial 
effects were known 5000 years ago in traditional Chinese 
medicine. The study of  the biological activities of  Ginkgo 
Biloba extract 761 (EGb 761), a standardized extract of  
Ginkgo Biloba with a well-defined mixture developed 
more than 20 years ago, has gained great popularity in 
European countries and the USA [13]. EGb 761 has 
been standardized to ensure the consistency of  its 
composition and a reliable, safe, efficacy profile [13]. The 
EGb 761 extract exhibits important properties, such as 
anti-oxidation, anti-apoptosis and anti-inflammation. At 
present, some studies [14-16] reports that EGb can take 
an anti-cancer role. Whether there was an association 
between EGb and Cox-2 / GST-Pi expression in the 
HCC risk rats induced by AFB1, there was no any 
report. In our study, we investigated the alteration of  
mRNA and protein expressions of  Cox-2 and GST-Pi 
in liver tissue in a rat with HCC risk, treated with EGb 
to explore the effect of  EGb on expressions of  Cox-2 
and GST-Pi in the pathogenesis of  HCC risk.
Materials and methods
Animal model
120 healthy male rats, 180g to 200g, of  Wistar 
backgrounds were purchased from the Experimental 
Animal center of  Guangxi Medical University, Nanning, 
China. All procedures were approved by the animal 
ethics committee of  Guangxi Medical University. The 
rats were divided into three groups at random: normal 
control group (control group), HCC risk group without 
treatment (HCC risk group), HCC risk group treated 
with EGb (EGb group); n=40, respectively. The risk 
of  HCC in rat was induced by intraperitoneal injection 
using aflatoxin B1 (AFB1) as follow: 4-7 weeks and 9-12 
weeks, 200μg/kg, thrice a week; 14-17 weeks, 19-22 
weeks, 24-27 weeks, and 29-32 weeks, 100μg/kg, twice 
a week; 34-73 weeks, 100μg/kg, once a week. The rats 
in EGb group were treated with EGb761 from the first 
week to the end (2g/kg.d; Sitexin, co.; Guilin, China). At 
the end of  13-week, 33-week, 53-week and 73-week, 10 
rats in each group were killed and the relevant samples 
were collected for molecular biology determination.
Real time reverse transcription polymerase chain 
reaction to detect Cox-2 and GST-Pi mRNA 
expression in liver tissue
Renal tissue was homogenized and total RNA was 
extracted with TRIzol (Beijing Tiangen, Co., China). 
Ultraviolet spectrophotometer measuring absorbance, 
agarose gel electrophoresis confirmed that there had 
been no degradation of  RNA by visualizing the 18S 
and 28S RNA bands under ultraviolet light [17, 18]. 
Primers of  were designed according to primer design 
principles by Primer Premier 5.0. The primers for 
Cox-2, GST-Pi and internal control β-actin were as 
follows: F 5’- CCTCGTCCAGATGCTATCTT-3’ 
and R 5’-GAAGGTGCTAGGTTTCCAG-3’ for Cox-
2;F5’-AGATGTCTGGCTTCAAGGCT-3’andR5’-
ATTTGCATCGAAGGTCCTCC-3’forGST-Pi;F5’-
GC C C C T G AG G AG C AC C C T G T-3’a n d R 5 ’ -
ACGCTCGGTCAGGATCTTCA-3’ for β-actin. 
One microgram total RNA from the liver tissue of  each 
rat was reverse transcribed into cDNA with an ExScript 
RT reagent kit (Fermentas). Cox-2, GST-Pi and β-actin 
were amplified with SYBR Premix Ex Taq (Beijing 
Tiangen, Co., China). Gene expression of  β-actin was 
also measured in each sample and used as an internal 
control for loading and reverse transcription efficiency. 
The analysis for each sample was performed in triplicate. 
The average threshold cycle (Ct, the cycles of  template 
amplification to the threshold) was worked out as the 
value of  each sample. The data for fold change was 
analyzed using 2−ΔΔCt [19, 20].
Immunohistochemical analysis of  Cox-2 and 
GST-Pi 
The operation was implemented using the streptavidin-
peroxidase immunohistochemical method. Renal tissue 
samples were fixed in 10% neutral formaldehyde, 
dehydrated with ethanol, and embedded in paraffin. 
Serial 4 μm sections were collected sequentially on glass 
slides. The paraffin was removed from the sections 
with xylene and rehydrated in graded ethanol. In order 
to retrieve antigenicity from formalin fixation, we 
incubated the sections for 10 min in 10 mmol/l sodium 
citrate buffer using a microwave oven. Endogenous 
peroxidase activity was blocked by further pretreatment 
with 3% hydrogen peroxide and methanol. Finally, the 
sections were incubated with antibody against GST-
Pi (Thermo Fisher Scientific, Co., Runcorn, UK), 
Cox-2 (Thermo Fisher Scientific, Co., Runcorn, UK) 
overnight at 4°C. The sections were washed thoroughly 
in phosphate-buffered saline (PBS) solution and 
incubated with rabbit anti-mouse biotinylated second 
antibody immunoglobulin (Shanghai Changdao, Co., 
Inc., China) for 30 min. Finally, the sections were stained 
with diaminobenizidine (Maixin Bio, Co., Inc., China). 
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We obtained negative controls by replacing specific 
antisera with PBS solution. Brownish yellow granular 
or linear deposits in the cells or matrix were interpreted 
as positive areas. Semi-quantitative evaluation was 
performed by computer-assisted image analysis (Leica 
Co., Germany). The positive staining of  Cox-2 or GST-
Pi was measured at 400-fold original magnification 
selected from coded sections of  each rat at random.
Western-blot analysis
The total proteins of  liver tissue were extracted using 
lysing buffer (Beyotime Institute of  Biotechnology, 
China), following a centrifugation at 12000g for 10 
minutes at 4°C, and protein content in the supernatant 
was detected using the BCA protein assay. Equal 
amounts of  extract (30 μg) were then separated on 
an 8% sodium dodecylsulfate (SDS)-poly-acrylamide 
gel and transferred by electroblotting to PVDF 
membranes. The membranes were incubated in 5% 
skimmed milk for one hour and were washed with 0.1% 
TBST at room temperature, and followed by overnight 
incubation at 4°C with primary antibodies: anti-GST-
Pi (Thermo Fisher Scientific, Co., Runcorn, UK), anti-
Cox-2 (Thermo Fisher Scientific, Co., Runcorn, UK) 
and anti-β-actin (1:5000, Epit Mics). Primary antibodies 
were diluted using 0.1% TBST. Alkaline phosphatase 
conjugated secondary antibodies were incubated with 
blots for one hour at room temperature. After washing, 
blots were developed by the ECL Western Blotting 
detection system, and then exposed to X-ray film for 
visualization of  the protein bands, and membranes 
were semi-quantified using the Quantity One image 
analysis system (4.3.1, Bio-Rad, USA). The expression 
level of  GST-Pi or Cox-2 was corrected by comparison 
with β-actin, and the final data were expressed used the 
fold chance. 
Statistical analysis
The data are shown as mean ± standard deviation (SD). 
To compare the groups in relation to parameters with 
normal distribution, One-way analysis of  variation 
(ANOVA) with post-hoc Fisher’s LSD (least significant 
difference) was used. For parameters without normal 
distribution, Kruskal-Wallis with post-hoc Mann-
Whitney (only for the weight parameter) was used (21, 
22). A value of  P < 0.05 was accepted as statistically 
significant. Statistical analysis was performed using the 
Statistical Package for Social Sciences (SPSS, version 
13.0; Chicago, IL, USA).
Results
The Cox-2 and GST-Pi mRNA expression in liver 
tissue
The mRNA expression of  Cox-2 in HCC risk group was 
similar to that of  control group in 13-week or 33-week, 
and the difference was not statistically significant (all 
P﹥0.05; Figure 1). Interestingly, the mRNA expression 
of  Cox-2 in HCC risk group was notably increased than 
that of  control group in 53-week and 73-week, and the 
difference was marked (all P<0.01; Figure 1). However, 
there was no statistical difference for mRNA expression 
of  Cox-2 between HCC risk group and EGb group in 
all the time points (all P﹥0.05; Figure 1). 
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Figure 1 The mRNA expression of  Cox-2 in three group. (: P﹥0.05 compared with control group; ): P﹥0.01 
compared with control group; §: P﹥0.05 compared with AFB1 group. 
 When compared with that in control group in 
all time points, the mRNA expression of  GST-Pi in 
HCC risk group was increased (all P<0.01; Figure 2). 
Interestingly, the difference of  mRNA expression of  
GST-Pi between HCC risk group and EGb group was 
no notably in 13-week, 33-week and 53-week. However, 
the mRNA expression of  GST-Pi in EGb group was 
marked attenuated than that in HCC risk group in 73-
week (P<0.01; Figure 2). 
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Figure 2 The mRNA expression of  GST-Pi in three group. (: P<0.01 compared with control group; ): P﹥0.01 
compared with AFB1 group; §: P﹥0.05 compared with AFB1 group.
Protein expressions of  Cox-2 and GST-Pi in liver 
tissue using immunohistochemical analysis
Immunohistochemical staining for Cox-2 was performed. 
The staining for Cox-2 was markedly enhanced in HCC 
risk group in 53-week or 73-week when compared with 
those in control group(all P<0.01; Figure 3), but the 
difference was not observed in 13-week or 33-week(all 
P﹥0.05; Figure 3). Furthermore, the difference of  
Cox-2 expression between HCC risk group and EGb 
group was not observed in 13-week, 33-week, 53-week 
or 73-week. The typical immunohistochemical staining 
firgure of  for Cox-2 in 73-week was shown in Figure 
3.
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Figure 3 Statistical parameters of  the protein expression of  Cox-2 and the typical immunohistochemical staining 
firgure for Cox-2 in three group. The protein expression of  Cox-2 in three group. (: P﹥0.05 compared with control 
group; ): P﹥0.01 compared with control group; §: P﹥0.05 compared with AFB1 group.
EGbAFB1Control
Immunohistochemical staining for GST-Pi was 
also conducted. The staining for GST-Pi was markedly 
enhanced in HCC risk group in 13-week, 33-week, 53-
week or 73-week when compared with those in control 
group (all P<0.01; Figure 4). The GST-Pi expression 
in EGb group in 73-week was marked reduced when 
compared with that in HCC risk group(P<0.01; Figure 
4). However, the difference of  GST-Pi expression 
between HCC risk group and EGb group was not 
observed in 13-week, 33-week, or 53-week (all P﹥0.05; 
Figure 4). The typical immunohistochemical staining 
firgure of  for Cox-2 in 73-week was shown in Figure 
4.
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Figure 4 Statistical parameters of  the protein expression of  GST-Pi and the typical immunohistochemical staining 
firgure for GST-Pi in three group. (: P<0.01 compared with control group; ): P﹥0.01 compared with AFB1 group; 
§: P﹥0.05 compared with AFB1 group. 
EGbAFB1Control
Protein expressions of  Cox-2 and GST-Pi in liver 
tissue using western-blot analysis
There was no statistical difference for the protein 
expression of  Cox-2 between HCC risk group and 
control group in 13-week and 33-week (all P﹥0.05; 
Figure 5). Interestingly, the protein expression of  Cox-2 
in HCC risk group was markedly increased than that 
of  control group in 53-week and 73-week, and the 
difference was notably (all P<0.05; Figure 5). There was 
no statistical difference for protein expression of  Cox-2 
between HCC risk group and EGb group in all the time 
points (each P﹥0.05; Figure 5). The typical blot bands 
for Cox-2 were presented in Figure 5
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1: AFB1 group, 2: EGb group, 3: control group.
Figure 5 Statistical parameters of  the protein expression of  Cox-2 and the typical blot bands for Cox-2 in three 
group. The protein expression of  Cox-2 in three group. (: P﹥0.05 compared with control group; ): P﹥0.01 
compared with control group; §: P﹥0.05 compared with AFB1 group.
The protein expression of  GST-Pi in HCC risk 
group was increased than that of  control group in all 
time points (all P<0.01; Figure 6). Interestingly, the 
difference of  protein expression of  GST-Pi between 
HCC risk group and EGb group was no notably in 
13-week, 33-week and 53-week. However, the protein 
expression of  GST-Pi in EGb group was marked 
attenuated than that in HCC risk group in 73-week 
(P<0.01; Figure 6). The typical blot bands for GST-Pi 
were presented in Figure 6.
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1: AFB1 group, 2: EGb group, 3: control group.
Figure 6 Statistical parameters of  the protein expression of  GST-Pi and the typical blot bands for GST-Pi in three 
group. (: P<0.01 compared with control group; ): P﹥0.01 compared with AFB1 group; §: P﹥0.05 compared with 
AFB1 group. 
Discussion
In this study, we found that Cox-2 expression in 
the HCC risk group was notably increased when 
compared with control group. Increased Cox-2 was 
associated with the risk of  HCC in rats. The results 
from real time reverse transcription polymerase chain 
reaction, immunohistochemical analysis and western-
blot analysis were consistent. Cox-2 might be taking 
part in the pathogenesis of  HCC. Over-expression 
of  Cox-2 has been reported to be associated with 
hepatocarcinogenesis. Ogunwobi et al. [23] reported 
that upregulation of  Cox-2 could promote epithelial-
mesenchymal transition and carcinogenesis in vitro, 
and could take part in the development of  HCC. 
Lee et al. [24] reported that the activation of  Cox-2 
signaling pathway had particular relevance to HCV-
associated HCC in patients with HCV-associated HCC. 
He et al. [25] reported that over-expression of  Cox-2 
in noncancerous liver regions was an independent and 
significant indicator predictive of  early recurrence of  
HCC in patients with HBV-related cirrhosis. Those 
results mentioned above indicated that over-expression 
of  Cox-2 was associated with the onset of  HCC. It was 
similar to the conclusion from our study. Cox-2 might 
take part in the pathogenesis of  HCC. 
     GST-Pi expression was also increased in the HCC risk 
group than that in control group. In our study, we found 
that the expression of  GST-Pi was increased step by step 
in the HCC risk group when compared with in control 
group. The results from real time reverse transcription 
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polymerase chain reaction, immunohistochemical 
analysis and western-blot analysis were consistent. 
Elevation of  GST-Pi was associated with the risk of  
HCC. There were also some reports finding that there 
might be a relationship between the expression of  
GST-Pi and the HCC risk. Yang et al. [26] reported 
that higher GST-pi expression mediated resistance to 
cisplatin in HCC cell line. Morsi et al. [27] reported that 
HCC patients had significantly higher serum GST-Pi. 
Niu et al. [28] found that the increased GST-Pi might be 
a marker enzyme for immunohistochemical detection 
of  human HCC and its preneoplastic lesions. The 
conclusion from those reports mentioned above was 
consistent with ours. So, increased GST-Pi might be 
associated with the onset of  HCC. 
    In our study, we found that the EGb had no effect 
on the expression of  Cox-2 in rats. Jang et al. [29] found 
that Cox-2 expression in the cambial meristematic cells 
was almost completely suppressed by EGb. Bao et al. 
[30] reported that EGb could inhibit the production 
of  Cox-2 in myocardial ischemia/reperfusion rats. 
Park et al. [31] found that EGb could inhibit the LPS-
induced Cox-2 in macrophage cell line. Our result was 
inconsistent with that from the studies mentioned 
above. However, there was no other report to study 
the relationship between EGb treatment and Cox-2 
expression in progress of  HCC. More studies on HCC 
risk should be performed in the future.  
    Interestingly, we found that EGb could take a 
protective role and regulate the expression GST-Pi. The 
GST-Pi expression was weakened when compared with 
that in HCC risk group in 73-week. There was only one 
study reporting the relationship between EGb treatment 
and GST-Pi expression. Sasaki et al. (32) reported that 
EGb significantly increased the protein level of  GST-Pi 
in the mouse liver. In our study, we didn’t found that 
EGb could reduce the GST-Pi expression in the rats 
with HCC risk. Its conclusion was similar to ours. We 
speculated that the EGb could take the protective role 
against HCC risk in rats by reducing the expression of  
GST-Pi, but not Cox-2. 
Conclussion
The expressions of  Cox-2 and GST-Pi were increased 
in the rats with HCC risk, and EGb could play a 
protective role against HCC risk in rats induced by 
AFB1 by reducing the expression of  GST-Pi, but 
not Cox-2, although the detailed mechanisms were 
not fully understood. At the moment, EGb is already 
used in clinical treatment for various diseases, such as 
thyroid carcinoma, Alzheimer’s disease and so on. In 
this investigation, we have demonstrated that EGb can 
protect against HCC risk in rats treated with AFB1. 
This observation might offer some new insights to 
prevent the onset of  HCC. However, cells culture and 
inhibition of  signaling pathway for EGb are needed to 
be conducted to be sure of  its effect and to explore the 
detailed mechanism. 
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